Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Juglans californica pollen is an allergenic extract derived from the pollen of the Juglans californica plant, also known as the California Black Walnut. [4, 5] It is marketed by Greer Laboratories, Inc. and was approved as a biologic (BLA101833) on September 15, 1981. [2] The product is indicated for the diagnosis (via skin testing) and treatment (via immunotherapy) of patients with immediate hypersensitivity allergies to California Black Walnut pollen. [2, 6] The mechanism of action involves modulating the body's immune response through cell-mediated immunity, leading to increased IgG production and desensitization to the allergen. [2] It is administered as a solution via intradermal, percutaneous, or subcutaneous routes. [2]
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Juglans californica pollen.